The Exeter Oncology Model: Renal Cell Carcinoma edition (EOM-RCC) is a platform cost-effectiveness model encompassing each decision node in the disease area for advanced renal cell carcinoma.

It has been constructed as part of the National Institute for Health and Care Excellence (NICE) Pathways Pilot appraisal (ID6186, GID-TA11186) [1] and the appraisal of cabozantinib plus nivolumab (TA964) [2] (formerly ID6184, whilst in development). The development of this model is described in Lee et al. 2024. [3]

This website was created by Amy Heather ORCID 0000-0002-6596-347. It shares model documentation to support understanding of how the model works, and how you can use it. Please use the sidebar to navigate through the site pages.

References

[1]
National Institute for Health and Care Excellence (NICE). Renal cell carcinoma Pathways Pilot [ID6186]. In development [GID-TA11186] n.d.
[2]
National Institute for Health and Care Excellence (NICE). Cabozantinib with nivolumab for untreated advanced renal cell carcinoma. Technology appraisal guidance [TA964] 2024.
[3]
Lee D, Burns D, Wilson E. NICE’s Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances. PharmacoEconomics - Open 2024. https://doi.org/10.1007/s41669-024-00490-x.